Quetiapine affects neuropeptide y and corticotropin-releasing hormone in cerebrospinal fluid from schizophrenia patients: Relationship to depression and anxiety symptoms and to treatment response

International Journal of Neuropsychopharmacology

Volumn 15, Issue 8, 2012, Pages 1051-1061

  Nikisch, Georg ^a   Baumann, Pierre ^b   Liu, Tianmin ^c   Mathé, Aleksander A ^c  

^a KLINIKUM FULDA   (Germany)

^b Hopital de Cery   (Switzerland)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CSF; neuropeptides; norquetiapine; quetiapine; schizophrenia

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; NEUROPEPTIDE Y; QUETIAPINE;

ADULT; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; IMMUNOREACTIVITY; LUMBAR PUNCTURE; MAJOR DEPRESSION; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; CORTICOTROPIN-RELEASING HORMONE; DIBENZOTHIAZEPINES; ELECTROCARDIOGRAPHY; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPEPTIDE Y; REGRESSION ANALYSIS; ROC CURVE; SCHIZOPHRENIA; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84864570224     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145711001556     Document Type: Article

References (90)

1. Adrian TE, Allen JM, Bloom SR, Ghatei MA, et al. (1983). Neuropeptide Y distribution in human brain. Nature 306, 584-586.
2. Afzal N, Thakore J (2009). Stress axis dysfunction: a common finding in schizophrenia and the metabolic syndrome? In: Thakore J, Leonard BE (Eds), Metabolic Effects of Psychotropic Drugs (pp. 82-89). Basel: Karger.
3. Allen YS, Adrian TE, Allen JM, Tatemoto K, et al. (1983). Neuropeptide Y distribution in rat brain. Science 221, 877-879.
4. Antonijevic IA, Murck H, Bohlhalter S, Frieboes RM, et al. (2000). Neuropeptide Y promotes sleep and inhibits ACTH and cortisol release in young men. Neuropharmacology 39, 1474-1481.
5. Banki CM, Bissette G, Arato M, O'Connor L, et al. (1987). CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia. American Journal of Psychiatry 144, 873-877.
6. Beal MF, Svendsen CN, Bird ED, Martin JB (1987). Somatostatin and neuropeptide Y are unaltered in the amygdala in schizophrenia. Neurochemical Pathology 6, 169-176.
7. Bernstein H-G, Dobrowolny H, Bogerts B (2007). Disturbed cross-talk between hypothalamic neuropeptides, nitric oxide and other factors may significantly contribute to the hyperactivity of the HPA axis in depression and schizophrenia. In: Levine BA (Ed.), Neuropeptide Research Trends (pp. 213-227). New York: Nova Science.
8. Berrettini WH, Doran AR, Kelsoe J, Roy A, et al. (1987). Cerebrospinal fluid neuropeptide Y in depression and schizophrenia. Neuropsychopharmacology 1, 81-83.
9. Brown JS (2009). Effects of bisphenol-A and other endocrine disruptors compared with abnormalities in schizophrenia: an endocrine disruption theory of schizophrenia. Schizophrenia Bulletin 35, 256-278.
10. Caberlotto L, Hurd YL (2001). Neuropeptide Y Y(1) and Y(2) receptor mRNA expression in the prefrontal cortex of psychiatric subjects. Relationship of Y(2) subtype to suicidal behavior. Neuropsychopharmacology 25, 91-97.
11. Ciccocioppo R, Gehlert DR, Ryabinin A, Kaur S, et al. (2009). Stress-related neuropeptides and alcoholism: CRH, NPY, and beyond. Alcohol 43, 491-498.
12. Cippitelli A, Rezvani AH, Robinson JE, Eisenberg L, et al. (in press). The novel, selective, brain-penetrant neuropeptide Y Y2 receptor antagonist, JNJ-31020028, tested in animal models of alcohol consumption, relapse, and anxiety. Alcohol.
13. Claes SJ (2004). Corticotropin-releasing hormone (CRH) in psychiatry: from stress to psychopathology. Annals of Medicine 36, 50-61.
14. Cohen H, Liu T, Kozlovsky N, Kaplan Z, et al. (in press). The neuropeptide Y (NPY)-ergic system is associated with behavioral resilience to stress exposure in an animal model of posttraumatic stress disorder. Neuropsychopharmacology.
15. Csernansky JG, Bardgett ME (1998). Limbic-cortical neuronal damage and the pathophysiology of schizophrenia. Schizophrenia Bulletin 24, 231-248.
16. Davis PC, Bravo O, Gehrke M, Azumaya CT (2010). Development and validation of an LC-MS/MS method for the determination of quetiapine and four related metabolites in human plasma. Journal of Pharmaceutical and Biomedical Analysis 51, 1113-1119.
17. Domschke K, Dannlowski U, Hohoff Ch, Ohrmann P, et al. (2010). Neuropeptide Y (NPY) gene: impact on emotional processing and treatment response in anxious depression. European Neuropsychopharmacology 20, 301-309.
18. Domschke K, Hohoff Ch, Jacob Ch, Maier W, et al. (2008). Chromosome 4q31-34 panic disorder risk locus: association of neuropeptide Y Y5 receptor variants. Neuropsychiatric Genetics 147, 510-516.
19. Eaton K, Sallee FR, Sah R (2007). Relevance of neuropeptide Y (NPY) in psychiatry. Current Topics in Medicinal Chemistry 7, 1645-1659.
20. Ehlers CL, Somes C, Seifritz E, Rivier JE (1997). CRF/NPY interactions: a potential role in sleep dysregulation in depression and anxiety. Depression and Anxiety 6, 1-9.
21. Fleischhacker WW, Kemmler G (2007). The clinical relevance of percentage improvements on the PANSS score. Neuropsychopharmacology 32, 2435-2436.
22. Flood JF, Hernandez EN, Morley JE (1987). Modulation of memory processing by neuropeptide Y. Brain Research 421, 280-290.
23. Forman SD, Bissette G, Yao J, Nemeroff CB, et al. (1994). Cerebrospinal fluid corticotropin-releasing factor increases following haloperidol withdrawal in chronic schizophrenia. Schizophrenia Research 12, 43-51.
24. Frederiksen SO, Ekman R, Gottfries CG, Widerlöv E, et al. (1991). Reduced concentrations of galanin, arginine, vasopressin, neuropeptide Y and peptide YY in the temporal cortex but not in the hypothalamus of brains from schizophrenics. Acta Psychiatrica Scandinavica 83, 273-277.
25. Fuxe K, Agnati LF, Harfstrand A, Zoli M, et al. (1990). On the role of neuropeptide Y in information handling in the central nervous system in normal and physiological states. Focus on volume transmission and neuropeptide Y/alpha 2 receptor interactions. Annals of the New York Academy of Sciences 579, 28-67.
26. Gabriel SM, Davidson M, Haroutunian V, Powchik P, et al. (1996). Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex. Biological Psychiatry 39, 82-91.
27. Goldstein JM, Christoph G, Grimmk S (2007). Unique mechanism of action for the antidepressant properties of the atypical antipsychotic quetiapine (poster). Presented at the Society of Biological Psychiatry's 62nd Annual Convention and Scientific Program; 17-19 May 2007, San Diego, CA.
28. Gruber SH, Nomikos GG, Mathe AA (2006). Effects of acute and subchronic d-amphetamine on ventral striatal concentrations of neurotensin and neuropeptide Y in rats treated with antipsychotic drugs. European Neuropsychopharmacology 16, 592-600.
29. Heilig M (2004). The NPY system in stress, anxiety and depression. Neuropeptides 38, 213-224.
30. Heilig M, Koob GF, Ekman R, Britton KT (1994). Corticotropin releasing factor and neuropeptide Y: role in emotional integration. Trends in Neurosciences 17, 80-85.
31. Heilig M, Widerlöv E (1990). Neuropeptide Y: an overview of central distribution, functional aspects, and possible involvement in neuropsychiatric illnesses. Acta Psychiatrica Scandinavica 82, 114-121.
32. Holsboer F (2003). The corticosteroid hypothesis of depression. Neuropsychopharmacology 23, 477-501.
33. Holsboer F, Ising M (2010). Stress hormone regulation: biological role and translation into therapy. Annual Review of Psychology 61, 81-109.
34. Huang XF, Deng C, Zavitsanou K (2006). Neuropeptide Y mRNA expression levels following chronic olanzapine, clozapine and haloperidol administration in rats. Neuropeptides 40, 213-219.
35. Husum H, Aznar S, Høyer-Hansen S, Larsen MH, et al. (2006). Exacerbated loss of cell survival, neuropeptide Y-immunoreactive (IR) cells, and serotonin-IR fiber lengths in the dorsal hippocampus of the aged flinders sensitive line 'depressed' rat: implications for the pathophysiology of depression? Journal of Neuroscience Research 84, 1292-1302.
36. Husum H, Mathé AA (2002). Early life stress changes concentrations of neuropeptide Y and corticotropinreleasing hormone in adult rat brain. Lithium treatment modifies these changes. Neuropsychopharmacology 27, 756-764.
37. Husum H, Mikkelsen JD, Hogg S, Mathé AA, et al. (2000). Involvement of hippocampal neuropeptide Y in mediating the chronic actions of lithium, electroconvulsive stimulation and citalopram. Neuropharmacology 39, 1463-1473.
38. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, et al. (2008). N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 33, 2303-2312.
39. Jiménez-Vasquez PA, Diaz-Cabiale Z, Caberlotto L, Bellido I, et al. (2007). Electroconvulsive stimuli selectively affect behavior and neuropeptide Y (NPY) and NPY Y(1) receptor gene expressions in hippocampus and hypothalamus of Flinders Sensitive Line rat model of depression. European Neuropsychopharmacology 17, 298-308.
40. Jiménez-Vasquez PA, Mathé AA, Thomas JD, Riley EP, et al. (2001). Early maternal separation alters neuropeptide Y concentrations in selected brain regions in adult rats. Brain Research. Developmental Brain Research 131, 149-152.
41. Jiménez-Vasquez PA, Overstreet DH, Mathé AA (2000). Neuropeptide Y in male and female brains of Flinders Sensitive Line, a rat model of depression. Effects of electroconvulsive stimuli. Journal of Psychiatric Research 34, 405-412.
42. Kalra SP, Clark JT, Sahu A, Dube MG, et al. (1988). Control of feeding and sexual behaviors by neuropeptide Y: physiological implications. Synapse 2, 254-257.
43. Karlsson RM, Choe JS, Cameron HA, Thorsell A, et al. (2008). The neuropeptide Y Y1 receptor subtype is necessary for the anxiolytic-like effects of neuropeptide Y, but not the antidepressant-like effects of fluoxetine, in mice. Psychopharmacology (Berlin) 195, 547-557.
44. Kasckow JW, Baker D, Geracioti TD (2001). Corticotropinreleasing hormone in depression and post-traumatic stress disorder. Peptides 22, 845-851.
45. Kash T, Winder D (2006). Neuropeptide Y and corticotropin-releasing factor bi-directionally modulate inhibitory synaptic transmission in the bed nucleus of the stria terminalis. Neuropharmacology 51, 1013-1022.
46. Kask A, Harro J (2000). Inhibition of amphetamine-and apomorphine induced behavioural effects by neuropeptide Y Y(1) receptor antagonist BIBO 3304. Neuropharmacology 39, 1292-1302.
47. Kay SR, Fiszbein A, Opler LA (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261-276.
48. Kerkerian L, Bosler O, Pelletier G, Nieoullon A (1998). Striatal neuropeptide Y neurones are under the influence of the nigrostriatal dopaminergic pathway: immunohistochemical evidence. Neuroscience Letters 66, 106-112.
49. Kronig MH, Munne RA, Szymanski S, Safferman AZ, et al. (1995). Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. American Journal of Psychiatry 152, 179-182.
50. Larhammar D, Salaneck E (2004). Molecular evolution of NPY receptor subtypes. Neuropeptides 38, 141-151.
51. Lewis DA, Moghaddam B (2006). Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Archives of Neurology 63, 1372-1376.
52. Mathé AA, Gruber S (2004). Neuropeptide Y has marked antidepressant properties in a rat model of depression. Neuropsychopharmacology 29 (Suppl. 1), 154.
53. Mathé AA, Husum H, El Khoury A, Jiménez-Vasquez P, et al. (2007). Search for biological correlates of depression and mechanisms of action of antidepressant treatment modalities. Do neuropeptides play a role? Physiology and Behavior 92, 226-231.
54. Mathé AA, Jiménez PA, Theodorsson E, Stenfors C (1998). Neuropeptide Y, neurokinin A and neurotensin in brain regions of Fawn Hooded 'depressed', Wistar, and Sprague Dawley rats. Effects of electroconvulsive stimuli. Progress in Neuropsychopharmacology and Biological Psychiatry 22, 529-546.
55. Mathé AA, Rudorfer MV, Stenfors C, Manji HK, et al. (1996). Effects of electroconvulsive treatment on somatostatin, neuropeptide Y, endothelin, and neurokinin A concentrations in cerebrospinal fluid of depressed patients: a pilot study. Depression 3, 250-256.
56. Michel MC, Beck-Sickinger A, Cox H, Doods HN, et al. (1998). XVI International Union of Pharmacology recommendations for the nomenculture of neuropeptide Y, peptide Y and pancreatic polypeptide receptors. Pharmacology Review 50, 143-150.
57. Morgan CA, Rasmusson AM, Winters B, Hauger RL, et al. (2003). Trauma exposure rather than posttraumatic stress disorder is associated with reduced baseline plasma neuropeptide-Y levels. Biological Psychiatry 54, 1087-1091.
58. Mottagui-Tabar S, Prince JA, Wahlestedt C, Zhu G, et al. (2005). A novel single nucleotide polymorphism of the neuropeptide Y (NPY) gene associated with alcohol dependence. Alcoholism: Clinical and Experimental Research 5, 702-707.
59. Nikisch G, Agren H, Eap CB, Czernik A, et al. (2005). Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. International Journal of Neuropsychopharmacology 8, 403-410.
60. Nikisch G, Baumann P, Kiessling B, Reinert M, et al. (2010a). Relationship between dopamine D2 receptor occupancy, clinical response, and drug and monoamine metabolites levels in plasma and cerebrospinal fluid. A pilot study in patients suffering from first-episode schizophrenia treated with quetiapine. Journal of Psychiatric Research 44, 754-759.
61. Nikisch G, Baumann P, Oneda B, Kiessling B, et al. (2011). Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study. Journal of Psychopharmacology 25, 896-907.
62. Nikisch G, Baumann P, Wiedemann G, Kiessling B, et al. (2010b). Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine. Correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. Journal of Clinical Psychopharmacology 30, 496-503.
63. Nikisch G, Mathé AA (2008). CSF monoamine metabolites and neuropeptides in depressed patients before and after electroconvulsive therapy. European Psychiatry 23, 356-359.
64. Obuchowicz E, Krysiak R, Herman ZS (2004). Does neuropeptide Y (NPY) mediate the effects of psychotropic drugs? Neuroscience and Biobehavioral Reviews 28, 595-610.
65. Peters J, Van Kammen DP, Gelernter J, Yao J, et al. (1990). Neuropeptide Y-like immunoreactivity in schizophrenia. Relationships with clinical measures. Schizophrenia Research 3, 287-294.
66. Pfennig A, Kunzel HE, Kern N (2005). Hypothalamuspituitary-adrenal system regulation and suicidal behavior in depression. Biological Psychiatry 57, 336-342.
67. Raison CL, Miller AH (2003). When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. American Journal of Psychiatry 160, 1554-1565.
68. Redrobe JP, Dumont Y, Herzog H, Quirion R (2003). Neuropeptide Y (NPY) Y2 receptors mediate behaviour in two animal models of anxiety: evidence from Y2 receptor knockout mice. Behavioural Brain Research 141, 251-255.
69. Redrobe JP, Dumont Y, Herzog H, Quirion R (2004). Characterization of neuropeptide Y, Y2 receptor knockout mice in two animal models of learning and memory processing. Journal of Molecular Neuroscience 22, 159-166.
70. Redrobe JP, Dumont Y, Quirion R (2002). Neuropeptide Y (NPY) and depression: from animal studies to the human condition. Life Sciences 71, 2921-2937.
71. Redrobe JP, Dumont Y, St-Pierre JA, Quirion R (2006). Multiple receptors for neuropeptide Y in the hippocampus: putative roles in seizures and cognition. Brain Research 8, 153-166.
72. Ryan MC, Sharifi N, Condren R, Thakore JH (2004). Evidence of basal pituitary overactivity in first episode, drug-naive patients with schizophrenia. Psychoneuroendocrinology 29, 4065-4070.
73. Sajdyk TJ, Fitz SD, Shekhar A (2006). The role of neuropeptide Y in the amygdala on corticotropin-releasing factor-mediated behavioral stress responses in the rat. Stress 9, 21-28.
74. Sapolsky RM (2002). Stress and plasticity in the limbic system. Reviews in the Neurosciences 13, 169-182.
75. Seedat S, Stein MB, Kennedy CM, Hauger RL (2003). Plasma cortisol and neuropeptide Y in female victims of intimate partner violence. Psychoneuroendocrinology 28, 796-808.
76. Shekhar A, Truitt W, Rainnie D, Sajdyk T (2005). Role of stress, corticotrophin releasing factor (CRF) and amygdala plasticity in chronic anxiety. Stress 8, 209-219.
77. Stanley BG, Leibowitz SF (1985). Neuropeptide Y injected in the paraventricular hypothalamus: a powerful stimulant of feeding behavior. Proceedings of the National Academy of Sciences USA 82, 3940-3943.
78. Strohle A, Holsboer F (2003). Stress responsive neurohormones in depression and anxiety. Pharmacopsychiatry 36, 207-214.
79. Tatemoto K, Carlquist M, Mutt V (1982). Neuropeptide Y-a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 296, 659-660.
80. Thorsell A (2010). Brain neuropeptide Y and corticotropinreleasing hormone in mediating stress and anxiety. Experimental Biology and Medicine 235, 1163-1167.
81. Thorsell A, Michalkiewicz M, Dumont Y, Quirion R, et al. (2000). Behavioral insensitivity to restraint stress, absent fear suppression of behavior and impaired spatial learning in transgenic rats with hippocampal neuropeptide Y overexpression. Proceedings of the National Academy of Sciences USA 97, 12852-12857.
82. Thorsell A, Slawecki CJ, EI Khoury A, Mathé AA, Ehlers CL (2006). The effects of social isolation on neuropeptide Y levels, exploratory and anxiety-related behaviors in rats. Pharmacology Biochemistry and Behavior 83, 28-34.
83. Valdez G, Koob G (2004). Allostasis and dysregulation of corticotrophin releasing factor and neuropeptide Y systems: implications for the development of alcoholism. Pharmacology, Biochemistry and Behavior 79, 671-689.
84. Walker R, Mittal V, Tessner K (2008). Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia. Annual Review of Clinical Psychology 4, 189-216.
85. Webster MJ, Knable MB, O'Grady J, Orthmann J, et al. (2002). Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Molecular Psychiatry 7, 985-994.
86. Widerlöv E, Lindstrom LH, Wahlestedt C, Ekman R (1988). Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively. Journal of Psychiatric Research 22, 69-79.
87. Widdowson PS, Ordway GA, Halaris AE (1992). Reduced neuropeptide Y concentrations in suicide brain. Journal of Neurochemistry 59, 73-80.
88. Yehuda R, Brand S, Yang RK (2006). Plasma neuropeptide Y concentrations in combat exposed veterans: relationship to trauma exposure, recovery from PTSD, and coping. Biological Psychiatry 59, 660-663.
89. Zech M, Roberts GW, Bogerts B, Crow TJ, et al. (1986). Neuropeptides in the amygdala of controls, schizophrenics and patients suffering from Huntington's chorea: an immunohistochemical study. Acta Neuropathologica 71, 259-266.
90. Zukowska-Grojec Z, Wahlestedt C (1993). Origin and actions of neuropeptide Y in the cardiovascular system. In: Colmers WF, Wahlestedt C (Eds), The Biology of Neuropeptide Y and Related Peptides (pp. 315-388). New Jersey: Humana Press.